4//SEC Filing
Hahn Mark W 4
Accession 0001104659-25-059403
CIK 0001657312other
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 4:31 PM ET
Size
6.0 KB
Accession
0001104659-25-059403
Insider Transaction Report
Form 4
Hahn Mark W
Chief Financial Officer
Transactions
- Sale
Ordinary Shares
2025-06-11$11.40/sh−400,000$4,560,360→ 12,278,992 total
Footnotes (4)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted on January 29, 2025.
- [F3]The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $11.375 to $11.4575 per Ordinary Share, inclusive (or $91.00 to $91.66 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]Consists of (i) 2,450,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 306,250 ADSs); and (ii) 9,828,992 Ordinary Shares underlying 1,228,624 ADSs.
Documents
Issuer
Verona Pharma plc
CIK 0001657312
Entity typeother
Related Parties
1- filerCIK 0001408502
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 4:31 PM ET
- Size
- 6.0 KB